Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Non-Current Assets (2016 - 2025)

Avanos Medical's Non-Current Assets history spans 11 years, with the latest figure at $1.2 billion for Q3 2024.

  • For Q3 2024, Non-Current Assets fell 1.39% year-over-year to $1.2 billion; the TTM value through Sep 2024 reached $4.8 billion, down 0.79%, while the annual FY2023 figure was $1.2 billion, 3.66% up from the prior year.
  • Non-Current Assets for Q3 2024 was $1.2 billion at Avanos Medical, roughly flat from $1.2 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.3 billion in Q1 2022 and bottomed at $1.2 billion in Q2 2023.
  • The 5-year median for Non-Current Assets is $1.2 billion (2023), against an average of $1.2 billion.
  • The largest annual shift saw Non-Current Assets grew 10.53% in 2022 before it decreased 11.85% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $1.2 billion in 2020, then decreased by 2.46% to $1.2 billion in 2021, then dropped by 1.12% to $1.2 billion in 2022, then grew by 3.66% to $1.2 billion in 2023, then decreased by 1.81% to $1.2 billion in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Non-Current Assets are $1.2 billion (Q3 2024), $1.2 billion (Q2 2024), and $1.2 billion (Q1 2024).